Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials

Vaccine
Wen-Qi DiaoBei He

Abstract

Data on the efficacy of the 23-valent pneumococcal polysaccharide vaccine (PPV-23) in preventing adult community-acquired pneumonia (CAP) among the target population of individuals aged over 65 years and high-risk individuals aged 19-64 years are conflicting. As the Advisory Committee on Immunization Practices (ACIP) has recently demonstrated PPV-23 is likely beneficial to immunocompromised adults by the Grading, Assessment, Development, and Evaluation (GRADE) framework, we conducted meta-analysis to examine its efficacy in an immunocompetent population. We searched the PUBMED, EMBASE, and Cochrane Library databases for randomized trials. Overall relative risks (RRs) with 95% confidential intervals (CIs) were calculated, and the Cochrane Q test (p, I(2)) was performed. Outcomes were assessed by the GRADE framework. Seven randomized trials involving 156,010 participants were included in this meta-analysis. High-quality evidence revealed that PPV-23 was weakly associated with the prevention of all-cause pneumonia ([RR] 0.87, [95%CI] 0.76-0.98, p=0.11, I(2)=43%), especially among the target population ([RR] 0.72, [95%CI] 0.69-0.94, p=0.58 I(2)=0%), the elderly group aged over 40 years ([RR] 0.80, [95%CI] 0.69-0.94) and the Japanes...Continue Reading

References

Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Jan 7, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Anke HussMatthias Egger
Jun 16, 2009·Lancet·Tom Jefferson
Jun 25, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·K DebbacheC Cordonnier
Feb 12, 2010·American Journal of Public Health·Yue Li, Dana B Mukamel
Aug 21, 2010·American Journal of Public Health·Deron C BurtonUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network
Jan 7, 2011·Journal of Clinical Epidemiology·Howard BalshemGordon H Guyatt
Jan 18, 2011·American Journal of Respiratory and Critical Care Medicine·Kevin C Wilson, Holger J Schünemann
Feb 28, 2013·Human Vaccines & Immunotherapeutics·Aba MahamatBenoît de Wzieres
Mar 25, 2014·Annals of Internal Medicine·Carolyn B BridgesUNKNOWN Advisory Committee on Immunization Practices
Mar 19, 2015·The New England Journal of Medicine·Marc J M BontenDiederick E Grobbee

❮ Previous
Next ❯

Citations

Dec 29, 2016·International Journal of Molecular Sciences·Nicola Principi, Susanna Esposito
Jul 1, 2017·PloS One·Hironori UematsuYuichi Imanaka
Feb 14, 2019·Expert Review of Vaccines·Andrew D WieseCarlos G Grijalva
Jul 4, 2019·Journal of Medical Microbiology·Lucia Gonzales-SilesEdward R B Moore
Jul 16, 2019·Expert Review of Vaccines·Viviane Maimoni GonçalvesEliane Namie Miyaji
Apr 3, 2018·Epidemiology and Infection·M SuzukiK Morimoto
Feb 15, 2021·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·David Felipe Severiche-BuenoLuis F Reyes
Apr 14, 2021·Value in Health Regional Issues·Jan OlbrechtBaudouin Standaert
Oct 14, 2021·BMC Infectious Diseases·Paula O NarváezLuis Felipe Reyes
Nov 9, 2021·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Chun-Yi LuYu-Fan Ho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.